Literature DB >> 21397948

Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis.

Mark A Greiner1, Jennifer Y Li, Mark J Mannis.   

Abstract

PURPOSE: To evaluate retention of visual acuity and development of complications after Boston type 1 keratoprosthesis implantation over a longer follow-up period than previously reported.
DESIGN: Cohort study. PARTICIPANTS: Forty eyes of 35 patients who underwent Boston type 1 keratoprosthesis surgery at the University of California, Davis, between 2004 and 2010.
METHODS: Preoperative, intraoperative, and postoperative parameters were collected and analyzed. MAIN OUTCOME MEASURES: Best-corrected visual acuity (BCVA) and postoperative complications.
RESULTS: Preoperative visual acuity ranged from 20/150 to light perception and was ≤20/400 in 38 eyes (95%). Preoperative diagnoses included failed corneal transplants (19 eyes, 47.5%), chemical injury (10 eyes, 25%), and aniridia (5 eyes, 12.5%). Mean follow-up duration was 33.6 months (range, 5-72 months). Of 36 eyes followed for ≥1 year, 32 eyes (89%) achieved postoperative BCVA ≥20/200. Of eyes that achieved BCVA ≥20/200, at last follow-up, 19 of 32 eyes (59%) followed for ≥1 year retained BCVA ≥20/200; 16 of 27 eyes (59%) followed for ≥2 years retained BCVA ≥20/200; 7 of 14 eyes (50%) followed for ≥3 years retained BCVA ≥20/200; and 2 of 7 eyes (29%) followed for ≥4 years retained BCVA ≥20/200. End-stage glaucoma most commonly caused vision loss (7 of 13 eyes, 54%) when BCVA ≥20/200 was not retained (follow-up ≥1 year). Glaucoma was newly diagnosed in 11 eyes (27.5%); progression was noted in 9 eyes (22.5%). Glaucoma drainage device erosion occurred in 9 eyes (22.5%). Retroprosthetic membrane formed in 22 eyes (55%), 5 eyes (12.5%) developed endophthalmitis, 6 eyes (15%) developed corneal melt, 7 eyes (17.5%) underwent keratoprosthesis replacement, and 23 eyes (57.5%) required major surgery to treat postoperative complications. The initial keratoprosthesis was retained in 32 eyes (80%).
CONCLUSIONS: Keratoprosthesis implantation remains a viable option for salvaging vision. A significant number of patients lost vision over the postoperative course. Glaucoma and complications related to glaucoma surgery are significant challenges to maintaining good vision after keratoprosthesis surgery. Our study highlights the need for long-term follow-up and a team approach to management, and points to a more guarded long-term visual prognosis after surgery. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21397948     DOI: 10.1016/j.ophtha.2010.12.032

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  33 in total

Review 1.  Corneal blindness and current major treatment concern-graft scarcity.

Authors:  Kah Hie Wong; Ka Wai Kam; Li Jia Chen; Alvin L Young
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

2.  Boston type 1 keratoprosthesis for failed keratoplasty.

Authors:  Jonathan L Hager; David L Phillips; Kenneth M Goins; Anna S Kitzmann; Mark A Greiner; Alex W Cohen; Jeffrey D Welder; Michael D Wagoner
Journal:  Int Ophthalmol       Date:  2015-05-16       Impact factor: 2.031

Review 3.  Fungal Infections After Boston Type 1 Keratoprosthesis Implantation: Literature Review and In Vitro Antifungal Activity of Hypochlorous Acid.

Authors:  Silvia Odorcic; Wolfgang Haas; Michael S Gilmore; Claes H Dohlman
Journal:  Cornea       Date:  2015-12       Impact factor: 2.651

4.  Boston keratoprosthesis type 1: outcomes of the first 38 cases performed at Moorfields Eye Hospital.

Authors:  Chameen Samarawickrama; Nicholas Strouthidis; Mark R Wilkins
Journal:  Eye (Lond)       Date:  2018-02-14       Impact factor: 3.775

5.  Artificial corneas versus donor corneas for repeat corneal transplants.

Authors:  Masako Chen; Sueko M Ng; Esen K Akpek; Sumayya Ahmad
Journal:  Cochrane Database Syst Rev       Date:  2020-05-13

6.  Anatomical survival and visual prognosis of Boston type I keratoprosthesis in challenging cases.

Authors:  Maria Fideliz de la Paz; Josef Stoiber; Valeria de Rezende Couto Nascimento; Juan Alvarez de Toledo; Orang Seyeddain; Wolfgang Hitzl; Günther Grabner; Rafael I Barraquer; Ralph Michael
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-25       Impact factor: 3.117

7.  Retention of the Boston keratoprosthesis type 1: multicenter study results.

Authors:  Joseph B Ciolino; Michael W Belin; Amit Todani; Khalid Al-Arfaj; Christopher J Rudnisky
Journal:  Ophthalmology       Date:  2013-03-15       Impact factor: 12.079

8.  Current Concepts in the Management of Unique Post-keratoplasty Infections.

Authors:  Julie M Schallhorn; Jennifer Rose-Nussbaumer
Journal:  Curr Ophthalmol Rep       Date:  2015-06-12

9.  High-resolution spectral domain anterior segment optical coherence tomography in type 1 Boston keratoprosthesis.

Authors:  Brett L Shapiro; Dennis E Cortés; Eric K Chin; Jennifer Y Li; John S Werner; Ellen Redenbo; Mark J Mannis
Journal:  Cornea       Date:  2013-07       Impact factor: 2.651

10.  Corneal graft dellen in a patient implanted with a Boston keratoprosthesis type 1.

Authors:  Riccardo Scotto; Aldo Vagge; Carlo E Traverso
Journal:  Int Ophthalmol       Date:  2016-04-11       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.